Mikrogen Diagnostics acquires Lophius Biosciences

12-Mar-2021 - The diagnostic company Mikrogen GmbH from Neuried is acquiring Lophius Biosciences GmbH from BioPark Regensburg to enter the future market of T-cell based tests. Immunodiagnostics plays a huge role in the fields of transplantation as well as infectious diseases and autoimmune disease. Lophius ...

Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR

20-Jul-2011 - Lophius Biosciences announced closing of an additional financing round totaling 1.4 million EUR. All current financial investors, such as S-Refit, High-Tech Gründerfonds (HTGF) as well as Bayernkapital participated in this financing round. The funds will be used for the market introduction of the ...

Lophius Biosciences Expands its Management Team

Preparation for Market Entry at the Beginning of 2012

14-Jul-2011 - Lophius Biosciences announced the expansion of its existing management team. In addition to its CEO, Dr. Michael Lutz, the CSO and cofounder Dr. Ludwig Deml, and the cofounder and Head of the Business Development, Dr. Nadja Prang, Lophius Biosciences will supplement its experienced management ...

Lophius Biosciences Announces Granting of Another Key Patent in the U.S.

19-Nov-2010 - Lophius Biosciences announced that the USTPO has granted the U.S. Patent US 78293318 entitled “Use of urea-adjuvanted polypeptides for diagnosis, prophylaxis and therapy“. This patent represents a key building block with respect to Lophius Biosciences T-cell based proprietary UREA technology ...

LOPHIUS closed 2nd financing round and appoints Dr. Michael Lutz as new CEO

19-May-2010 - Lophius Biosciences announced that the company has successfully closed a 2nd round financing with a value of around 1,6 m EUR. The investment of S-Refit, the new lead investor, is strongly supplemented by follow up investments from existing investors High-Tech Gruenderfonds and Bayernkapital. The ...